MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH) this week announced the expansion of its team through the addition of new employees primarily in the areas of analytical development, business development, sales and marketing to support our continued growth and customer diversification efforts.
Inducement Equity Award
In connection with the hiring of these personnel, the compensation committee of Recro’s board of directors approved inducement stock option grants to purchase an aggregate of 98,843 shares of Recro’s common stock.
The equity awards were granted pursuant to the NASDAQ inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with Recro in accordance with NASDAQ Listing Rule 5635(c)(4).
The option awards were granted on March 31, 2021, and will have an exercise price equal to the closing price of Recro’s common stock on March 31, 2021. The options have a ten-year term and vest in equal monthly installments over four years. The equity awards are subject to each individual’s continued service with Recro through the applicable vesting dates.
Headquartered in Malvern, Recro is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.